Being spotted in multiple cancer types, lymph node (LN) metastasis literally is the symbol of dreadful patient outcomes, characterizing poor prognosis and shorter survival. Recent research has highlighted sentinel LNs as the gateway for haematogenous metastasis, and this recognition has opened a window for further exploration of possible control measures for LN metastasis other than conventional surgical and radiological methods that bring suboptimal results. As the increased internal pressure of LNs due to tumour growth will limit the penetration of anti-cancer drug, a research team from Tohoku University of Japan developed a novel lymphatic drug delivery system (LDDS). The technique utilizes ultrasound to guide the administered drugs directly into target LNs as well as secondary LNs located downstream in the lymphatic network. The team proved the utility of LDDS by administering docetaxel at specific osmotic pressure and viscosity (1,960 kPa, 12 mPa·s) in a preclinical model of a metastatic LN mouse model. The LDDS yielded promising therapeutic outcomes with increased complete response, prolonged survival, and reduced adverse events, shedding light on meeting the unmet needs in improved LN metastasis management.